Results 21 to 30 of about 119,805 (200)
Pathogens, 2021 Powassan virus (POWV) is a tick-borne flavivirus circulating in North America and the Russian Far East that can cause severe neuroinvasive diseases, including encephalitis, meningitis, and meningoencephalitis.
Velasco Cimica +6 more
doaj +1 more source
Virus-Like Particle Production in Atmospheric Eubacteria Isolates
Atmosphere, 2019 Culturable eubacterial isolates were collected at various altitudes in Earth’s atmosphere, including ~1.5 m above ground in Tallahassee, FL, USA; ~10.0 m above sea level over the mid-Atlantic ridge (~15° N); ~20 km above ground over the ...
Nuria Teigell-Perez +4 more
doaj +1 more source
Vaccines, 2021 Virus-like particles (VLPs) are non-replicative vectors for the delivery of heterologous epitopes and are considered one of the most potent inducers of cellular and humoral immune responses in mice and guinea pigs.
Muhammad Naveed Anwar +14 more
doaj +1 more source
Virus-Like Particle, Liposome, and Polymeric Particle-Based Vaccines against HIV-1
Frontiers in Immunology, 2018 It is acknowledged that vaccines remain the best hope for eliminating the HIV-1 epidemic. However, the failure to produce effective vaccine immunogens and the inability of conventional delivery strategies to elicit the desired immune responses remains a ...
Yong Gao +2 more
doaj +1 more source
Norwalk virus-like particles as vaccines [PDF]
Expert Review of Vaccines, 2010 Noroviruses (NoV) cause the great majority of epidemic nonbacterial gastroenteritis in humans. Expression of the capsid protein in recombinant systems, including insect and plant cells, yields assembly of virus-like particles (VLPs) that mimic the antigenic structure of authentic virions, and are relatively acid- and heat-stable.
Melissa, Herbst-Kralovetz +2 more
openaire +2 more sources
The 5th virus-like particle and nano-particle vaccines (VLPNPV) conference
Expert Review of Vaccines, 2019 Virus-like particles (VLPs) and nano-particles (NPs) are promising vaccine platforms that have led to the successful development of commercially available vaccines.
Paul Engeroff, Martin F. Bachmann
doaj +1 more source
Virus-like particle vaccine protects against 2009 H1N1 pandemic influenza virus in mice. [PDF]
PLoS ONE, 2010 The 2009 influenza pandemic and shortages in vaccine supplies worldwide underscore the need for new approaches to develop more effective vaccines.We generated influenza virus-like particles (VLPs) containing proteins derived from the A/California/04/2009
Fu-Shi Quan +3 more
doaj +1 more source
Escherichia coli-derived virus-like particles in vaccine development
npj Vaccines, 2017 Recombinant virus-like particle-based vaccines are composed of viral structural proteins and mimic authentic native viruses but are devoid of viral genetic materials. They are the active components in highly safe and effective vaccines for the prevention
Xiaofen Huang +4 more
doaj +1 more source
Hepatitis B Virus (HBV) Subviral Particles as Protective Vaccines and Vaccine Platforms
Viruses, 2020 Hepatitis B remains one of the major global health problems more than 40 years after the identification of human hepatitis B virus (HBV) as the causative agent.
Joan Kha-Tu Ho +2 more
doaj +1 more source
Multiplex Human Papillomavirus L1L2 virus-like particle antibody binding assay
MethodsX, 2022 A variety of in vitro techniques are available to estimate the level of antibodies present in human serum samples. Such tests are highly specific and are used to determine prior exposure to a pathogen or to estimate the magnitude, breadth and durability ...
Kavita Panwar +7 more
doaj +1 more source